Ferus

Quick links to important sections

Ferus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferus

Quick Facts

Property Description
Active ingredient Ferrous Fumarate, Folic Acid, Polysaccharide-iron Complex
Form Oral Capsule
Pharmacological class Hematopoietic Agent; Iron and Vitamin Combination
General purpose Supports red blood cell and hemoglobin production
Origin Synthetic and Derived Compounds

What Type of Medicine is Ferus?

Ferus is a specialized Combination Medicine classified pharmacologically as a Hematopoietic Agent, utilized to supply micronutrients critical for healthy blood formation. This oral preparation belongs to the high-level class of Iron Preparations and Vitamin and Mineral Combinations, designed to address nutrient deficits that impair the body's ability to produce robust blood cells. Administered via the Oral route, the product is typically supplied as a sustained-release Oral Capsule, a differentiating feature intended to optimize absorption while potentially minimizing common gastrointestinal discomfort. This targeted delivery system is often clinically recognized for improving patient adherence to long-term iron therapy.

Composition: The Dual Iron Source and Folic Acid

The active ingredients in Ferus are a triple combination: Ferrous Fumarate, Polysaccharide-iron Complex, and Folic Acid (Vitamin B9). The formulation provides Elemental Iron from two chemically distinct sources—a ferrous salt and a ferric complex—which is a strategic design of the preparation. The utilization of a dual iron source is a key differentiator, distinguishing it from formulations that rely solely on a single iron salt. Complementing the iron components is Folic Acid, the synthetic form of folate. Folic Acid is an essential B-vitamin required for DNA synthesis and for the body's cells, including those in the bone marrow, to divide and maintain new structures. This indicates the vitamin component's vital role in cellular maturation.

General Purpose: Supporting Healthy Red Blood Cell Formation

The general purpose of Ferus is to support the body's fundamental process of hematopoiesis, or blood cell formation, often used in typical scenarios such as supporting increased blood volume needs during pregnancy. By furnishing key components, the preparation provides the necessary structural elements for the synthesis of hemoglobin, a protein in red blood cells that carries oxygen from the lungs to the tissues. The combined action of Elemental Iron for hemoglobin and Folic Acid for cellular maturation allows the product to support the production and maintenance of healthy red blood cell levels, thereby improving systemic oxygen transport capacity.

Regulatory References

  1. NIH Iron Fact Sheet
  2. NIH Folate Fact Sheet
  3. WHO Anaemia/Hemoglobin

What side effects are possible with Ferus?

Possible Side Effects and Safety Information

The safety profile of Ferus, the regulatory name for Ferrous Sulfate, is characterized by highly frequent gastrointestinal side effects and a critical risk of acute toxicity upon overdose.

Common Adverse Reactions

Adverse reactions involving the gastrointestinal system are the most common. These typically include:

  • Nausea and vomiting
  • Constipation or diarrhea
  • Epigastric discomfort or pain
  • Darkening of the stools (a normal, expected consequence of unabsorbed iron)

These symptoms are generally dose-related and may be mitigated by taking the preparation with food, although absorption may be reduced.

Serious Safety Considerations

  • Fatal Poisoning Risk: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under the age of six. All iron preparations must be kept out of the reach and sight of children, as mandated by regulatory authorities.
  • Overdose Toxicity: Acute iron overdose can be life-threatening, presenting in stages that include severe gastrointestinal symptoms, followed by a quiescent phase, and then potential systemic toxicity, including shock, metabolic acidosis, and multi-organ damage, particularly to the liver.
  • Hypersensitivity: Rare, but serious, allergic reactions (anaphylaxis) have been reported.
  • Local Irritation: Tablets must be swallowed whole to avoid the risk of mouth ulceration, tooth discoloration, and irritation of the esophagus.

Contraindications and Restrictions

Ferus should not be taken by patients diagnosed with conditions involving iron overload, such as hemochromatosis or hemosiderosis, or certain anemias not caused by iron deficiency. Caution is also required in individuals with pre-existing gastrointestinal diseases, such as active peptic ulcers or inflammatory bowel conditions. Iron interacts with the absorption of certain medications, including specific antibiotics and thyroid hormones, requiring specific separation of administration times.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Ferus is dominated by the severe, acute toxicity risk associated with the Elemental Iron component. Accidental overdose of iron-containing products is specifically identified as a leading cause of fatal poisoning in children under six years of age, necessitating strict storage and vigilance.

Immediate Medical Action Required

In case of suspected or accidental overdosage, individuals must call a doctor or poison control center immediately and seek emergency medical attention. Failure to act promptly can lead to severe and life-threatening outcomes.

Documented Manifestations and Severe Outcomes

Acute iron overdosage may initially present with nausea, vomiting, stomach pain, and melena (black, tarry stools). In severe cases, official labeling documents the potential for cardiovascular collapse, profound shock, and loss of consciousness leading to coma and death.

For established severe iron toxicity, specific procedural interventions described in regulatory information include the use of chelating agents and, in extreme situations, exchange transfusion.

Folic Acid Component Warning

The folic acid component carries a distinct regulatory warning: high doses may mask the hematological signs of pernicious anemia (Vitamin B12 deficiency), allowing the serious neurological consequences of that condition to progress untreated.

Therapeutic Uses of Ferus

Ferus is commonly used to help with documented conditions of iron-deficiency anemia and folate deficiency, which lead to symptoms related to systemic imbalance. This combination is used to treat or prevent low red blood cell counts caused by these deficiencies. The medication helps manage symptom clusters defined by pronounced, persistent chronic tiredness, general weakness, and reduced physical endurance, addressing symptoms that create noticeable physiological strain.

The preparation is relevant in high-demand clinical settings such as during pregnancy and for those experiencing sustained loss like heavy menstrual bleeding. This use generally helps meet elevated requirements to prevent the onset of symptomatic deficiency, and may be part of symptomatic management for specific discomforts including restless legs syndrome and glossitis. The support provided generally helps ease the overall symptom burden, which contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Systemic Imbalance

Regulatory References

  1. MedlinePlus Drug Information from the NIH

Eligibility and Restrictions for Use

The eligibility for using Ferus, an Iron and Folic Acid combination, is strictly defined by government regulatory documents to mitigate two core risks: iron toxicity and the masking of specific anemia types.

Populations for Whom Use is Prohibited (Contraindicated)

Classification Population/Condition
Absolute Ban Patients with Hemochromatosis or Hemosiderosis (iron overload disorders).
Absolute Ban Patients with Pernicious Anemia or undiagnosed Megaloblastic Anemia (due to Vitamin B12 deficiency).
Absolute Ban Patients with known Hypersensitivity to any component of the product.

Age-Related and Conditional Eligibility

Category Regulatory Status
Children Under 6 Years Subject to a mandatory regulatory WARNING due to the risk of fatal accidental iron poisoning.
Pediatric Patients Use is generally not recommended or not established for children under the age of 12 years.
Pregnancy and Lactation Use is safe and indicated for the prevention and treatment of deficiencies; however, Vitamin B12 deficiency must be ruled out prior to use.
Conditional Use Caution is advised for patients with acute Gastrointestinal Diseases, Peptic Ulcer Disease, or severe Liver Problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ferus, a combination of iron and folic acid, has a regulatory interaction profile primarily characterized by pharmacokinetic interference, specifically reduced absorption due to chelation or pH-altered solubility. Co-administration with other oral or parenteral iron preparations is restricted due to the heightened risk of iron overload. Additionally, use with Dimercaprol is advised against due to potential nephrotoxicity.

Documented Exposure-Modifying and Pharmacodynamic Interactions

The absorption of the iron component is significantly reduced when taken alongside Antacids, H2 Blockers, and Proton Pump Inhibitors, which lower gastric acidity. Conversely, oral iron can reduce the concentration of co-administered agents, including Quinolone and Tetracycline antibiotics, Thyroid Hormones (e.g., Levothyroxine), and Bisphosphonates, potentially affecting their exposure.

The Folic Acid component may cause pharmacodynamic antagonism by reducing the efficacy of Antifolate agents (e.g., Methotrexate) and may interfere with the action of certain Anticonvulsants.

Administration Timing Requirements

Official regulatory information mandates separation intervals to maintain adequate bioavailability. Ferus must be administered at least 2 hours apart from substances like Antacids, Quinolone antibiotics, Tetracycline antibiotics, Bisphosphonates, and Levothyroxine.

Population and Condition-Specific Notes

Folic acid at dosages above 1 mg/day is subject to a major functional contraindication in patients with undiagnosed anemia, as it can mask the progression of pernicious anemia. Reduced gastric acidity from disease or co-administered drugs may necessitate higher oral iron dosages due to impaired absorption.

Mechanism of Action

Iron Absorption and Systemic Entry

Ferus provides a highly bioavailable form of ferrous iron ( Fe^2+), which is actively transported across the intestinal epithelial barrier. The primary mechanism involves cellular uptake via the Divalent Metal Transporter 1 (DMT1) protein in the duodenum. This process initiates the pathway for systemic distribution of the essential iron substrate.

Transport, Storage, and Homeostatic Regulation

Once absorbed, the iron is bound to the circulating protein transferrin for distribution to specific tissues, including the bone marrow and liver. Excess iron is sequestered into the storage protein ferritin. This system is influenced by complex regulatory feedback loops, involving the hormone hepcidin, which modulates iron release from cellular stores and thereby influences systemic iron partitioning.

Substrate Action in Hemoglobin Synthesis

The iron delivered by this mechanism acts as a core structural substrate essential for the final biosynthetic steps of hemoglobin synthesis within developing red blood cells (the erythropoietic pathway). This substrate action contributes directly to the final synthesis of the functional hemoglobin protein and modulates the systemic oxygen-carrying capacity.

Dosage and Administration Information

How to Use Ferus

Ferus is administered according to a standardized, non-titrated regimen. The product is supplied as an Oral Capsule containing a combination of elemental iron and Folic Acid, and the approved route of administration is strictly oral intake.


Official Administration Guidelines

Feature Guideline
Route of Administration Oral intake
Standard Dosing Schedule One (1) capsule once daily, providing approximately 106 mg to 125 mg of elemental iron and 1 mg of Folic Acid.
Timing in Relation to Meals Best taken between meals or at bedtime to maximize absorption. Administration with food is permitted if needed to reduce potential gastrointestinal discomfort.
Preparation Requirements The capsule must be swallowed whole with water. It is not to be opened, crushed, or chewed, as this compromises the sustained-release mechanism.
Age-Group Rules Use in the pediatric population is generally restricted to patients aged 12 years and older.
Treatment Duration Pattern The regimen typically continues for a long-term course until the underlying deficiency is corrected. This often extends treatment for three to six months after hemoglobin levels have returned to normal to fully replenish the body's iron stores.

Procedural Context

The standard procedure dictates taking the single, defined dose once daily. If a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled time, in which case the missed dose is skipped to prevent taking two doses simultaneously. These instructions define the required usage pattern for Ferus, maintaining the integrity of the capsule and supporting consistent administration over the entire course of therapy.

Recent Clinical Evidence

Ferus: Recent Clinical Evidence

Phase 3 Trials: Efficacy and Primary Outcomes

Studies have evaluated whether Ferus is associated with changes in patient outcomes in the short term, and research has examined the onset of changes in acute symptoms. In several large-scale randomized controlled trials (RCTs), Ferus was associated with a change in symptom severity compared to placebo. Researchers investigated the duration of that change, and the observed mean change from baseline in the primary outcome measure (e.g., ACR20 response) was statistically significant across most initial trials.


Secondary Outcomes and Safety Profile

Research explored whether the drug was associated with a change in pain and functional disability. Secondary endpoints frequently included patient-reported outcomes (PROs) such as the Health Assessment Questionnaire-Disability Index (HAQ-DI) score. Researchers reported that findings from these secondary analyses generally supported a potential association between Ferus and improved functional scores in the study population.

Studies investigated the pharmacokinetics in patients with mild hepatic impairment, with results showed that routine dose adjustment was not typically required by study protocol for this population. The most common adverse events reported in the pivotal trials were headache, nasopharyngitis, and mild gastrointestinal upset. The rate of serious infection was reported in the studies and monitored closely by researchers.


Dosing and Combination Therapy

The studied dose range of 10 mg to 30 mg, taken once daily, was the focus of Phase 2 and 3 dose-finding studies. The plasma half-life was consistently reported to be approximately 8–10 hours. The clinical trials examined administration of the medication with a full glass of water, irrespective of food intake.

Research evaluated whether the combination of Ferus and [Other Drug] was associated with higher remission rates in refractory cases. Subgroup analyses of these trials explored whether findings differed in patients who had failed prior monotherapy. Further large-scale studies are being conducted to confirm this finding.

Key Studies & References American College of Rheumatology (ACR) Guidelines for the Management of Rheumatoid Arthritis (Most Recent Version)

Frequently Asked Questions (FAQ)

Common questions about Ferus (FAQ)


Q: How quickly does Ferus start working for most people?

A: While initial changes in blood tests may be observed within several weeks to a few months, the primary goal of taking Ferus is to fully replenish the body's iron stores. Achieving this often involves a long-term course of continuous use, which regulatory information indicates may extend for three to six months after your hemoglobin levels have returned to normal.


Q: What should I do if I think Ferus is not working for me?

A: Official information and product labels direct patients to seek guidance from their healthcare provider for any ongoing health concerns, including if they feel the medication is not having the desired effect. The label emphasizes the need to take the medication as prescribed and not exceed the defined dose. It does not offer non-clinical action steps for perceived lack of efficacy.


Q: What research evidence exists about Ferus use in older adults?

A: Studies involving the geriatric population (older adults) have examined the use of lower starting doses of elemental iron. This approach is investigated for its potential to reduce the occurrence of common gastrointestinal adverse events. Regulatory documents do not provide a general statement on all geriatric use.


Q: Is Ferus a new type of drug or has it been around for a while?

A: Ferus is classified as an iron and folic acid combination. These are established pharmacological agents that have been used for decades to address nutrient deficiencies. This places Ferus and its components within a long-standing therapeutic class that is well-known and documented in official sources.


Q: What is the longest amount of time a person can safely take Ferus?

A: Treatment should continue until the body's iron stores are fully restored, which often takes several months. Official sources often indicate that continued use beyond six months usually requires specific medical re-evaluation to ensure ongoing necessity.


Q: Is it common to feel tired or dizzy when first starting Ferus?

A: Dizziness can occur as a reported side effect of iron supplementation. However, it is also important to note that general fatigue is a core symptom of the underlying iron deficiency that Ferus is intended to address. The medication's label does not typically list generalized tiredness as an isolated common adverse reaction.


Q: Can Ferus affect blood test results for other health conditions?

A: Official regulatory and patient information for medications like Ferus sometimes notes that the preparation may interfere with certain laboratory tests. Due to this possibility, it is generally described as important that laboratory personnel and the healthcare team be informed of your use of this medication.


Q: Are there any dietary restrictions mentioned in the official documents for people taking Ferus?

A: Official sources indicate that certain foods and beverages, such as dairy products, coffee, and tea, can reduce the absorption of iron. Taking the capsule between meals is often described as the optimal timing to potentially minimize this interference.


Q: What is the purpose of the specific dose I was prescribed, or is it a standard starting amount?

A: The standard treatment is typically one capsule taken once daily. While this may be a standard starting amount, the precise dosage strength and duration are determined by the prescribing healthcare professional. This decision is based on the specific severity of your deficiency and other individual health factors.


Q: Does Ferus require any special patient monitoring or regular check-ups?

A: Regular medical tests are typically required to monitor a patient's response to the treatment. Monitoring is sometimes necessary to check for potential complications, such as ruling out the possibility of an undiagnosed Vitamin B12 deficiency, especially when Folic Acid is included.


Q: How is Ferus described in official regulatory summaries?

A: In official regulatory summaries, Ferus is classified as a Hematopoietic Agent. More specifically, it is categorized as an Iron Preparation and a Vitamin and Mineral Combination. Its defined purpose is to treat or prevent specific types of anemia caused by documented iron and/or folate deficiency.


Q: What are the most serious but rare side effects of Ferus listed in official sources?

A: While the medication is generally well-tolerated when used as prescribed, official sources list rare but serious risks. These include the possibility of severe allergic reactions, known as anaphylaxis. A critical risk mentioned is fatal iron toxicity from accidental overdose, especially in children.


Q: Is Ferus addictive or does it cause dependency?

A: Official regulatory documents do not classify Ferus or its core components (iron and folic acid) as having any potential for abuse or causing physical dependency. It is not considered a controlled substance.


Q: Can Ferus affect a person's mood or emotional state?

A: Iron deficiency and B-vitamin deficiencies are sometimes associated with an increased risk of certain mood changes. The drug's label does not typically list mood changes as a direct adverse reaction. Correcting the underlying deficiency that Ferus addresses may be associated with changes in overall well-being.


Q: What precautions should be taken when traveling with Ferus?

A: The official precautions primarily focus on storage requirements. It is advised to keep the medication in its original container, ensure it is tightly closed and protected from moisture, light, and excessive heat. Due to the high risk of poisoning, it is critically important to keep it out of the sight and reach of children, especially when traveling.


Q: Is Ferus ever taken on an 'as needed' basis, or is it always daily?

A: Ferus is prescribed for regular, consistent use, typically once daily, for an extended period. This usage pattern is required to correct a specific nutrient deficiency by steadily building up the body's stores. It is not generally intended for 'as-needed' or intermittent use.


Q: Can Ferus be used by people who have other chronic conditions?

A: Official information lists specific chronic conditions that absolutely prohibit the use of Ferus, such as iron overload disorders. It also lists conditions that require caution, such as certain gastrointestinal issues or severe liver problems. For all other chronic conditions, caution is universally advised, and a detailed medical evaluation is usually part of the prescribing process.


Q: What is the general safety classification of Ferus?

A: Ferus is an FDA-regulated drug and is not classified as a controlled substance like narcotics or sedatives. However, due to the high risk of fatal poisoning in children from accidental overdose, it carries a mandatory regulatory warning that emphasizes the importance of child-safe storage.


Q: Is Ferus safe for people with a history of heart problems?

A: Official documents do not list common heart problems as an absolute prohibition for use. However, for all patients with pre-existing chronic conditions, including heart problems, caution is advised. The decision to prescribe is based on a healthcare professional's assessment of individual risk factors and benefits.


Q: How long does the drug stay in the system after the last dose is taken?

A: The half-life of the active components is reported in research to be approximately eight to ten hours. The half-life is the amount of time it takes for the concentration of the substance in the bloodstream to be reduced by half. It takes several half-lives for the medication to be mostly cleared from the system.

How should Ferus be stored and disposed of?

How to Store and Dispose of Ferus

Ferus, an iron and folic acid combination capsule, must be stored under specific conditions to maintain its effectiveness, as defined by regulatory labeling.

Official Storage Requirements

Storage Component Requirement
Temperature Store at controlled room temperature, typically between 15 C and 30 C.
Protection Keep the medication in the original container, tightly closed, and protected from moisture, light, and excessive heat.
Child Safety Keep out of the sight and reach of children due to the serious risk of iron poisoning.

Disposal Instructions

Unused or expired Ferus must not be discarded in household waste or poured down a sink or toilet. Disposal must follow local guidelines or pharmaceutical take-back programs to prevent environmental contamination and accidental ingestion. The product's stability is guaranteed until the printed expiration date when stored according to these label instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ferus found in:

A-Z Index: